

Analgesics - antipyretics



= „weak“ analgesics

= non-opioid analgesics


Most of them also

- non-steroidal anti-inflammatory drugs (NSAIDs)
- antirheumatics

Metabolism of eicosanoids



inhibitors of prostaglandins synthesis = = "weak" analgesics + + NSAIDs



Effects of prostaglandins

Prostaglandin E, F_{2 α} : mediators of ache, fever, inflammation; secretion of HCl↓, stomach mucosa capillaries dilation, contraction of uterus, kidneys: excretion of Na⁺ and H₂O ↑

Prostacyclin (prostaglandin I₂): vasodilation, platelets aggregation inhibition

Tromboxan: vasoconstriction, platelets aggregation activation

Leukotriens: allergic reactions (e.g. asthma bronchiale)


Cyclooxygenases (= prostaglandin G/H synthases)

COX1

Constitutive: in all the tissues

Functions:

- protection of stomach mucosa (vasodilation)
- diuresis
- platelets aggregation (TXA)



Philipp Niedermann

COX2

Constitutive: kidneys, brain (co-localized with cyclins D₁ and E)

discoverer of COX isoenzymes

Inducible: macrophages, neutrophils, fibroblasts, endothelium cells

(1989)

Functions:

- vasodilatation (PG I₂)
- childbirth (uterus contractions)
- inflammation processes

COX3 ?? (= COX1b; brain ?)

Classification of COX inhibitors

(antipyretics, NSAIDs)

Non-selective (COX1 + COX2)

- Anilides
- Salicylates
- Phenamates
- Aryl- and heteroaryl alkanoic acids
 - Aryl- and heteroaryl acetic acids
 - Aryl- and heteroaryl propionic acids


- Oxicams
- 1,2-Dihydropyrazolidine-3-ones
- 2,5-Pyrazolidinediones

Selective (COX1<COX2): nimesulide

Specific (COX2)

- Coxibes


Anilides



acetanilide


N-phenylacetamide

1886: Antifebrin®



**paracetamol
(acetaminophen)**
4-(acetylamino)phenol

***para*-(acetylamino)phenol**
***p*-(acetylamino)phenol**
Paralen®, Panadol®....




phenacetin
N-(4-ethoxyphenyl)acetamide

nephrotoxicity

Dinyl® - analg.
mixture with caffeine,
aminophenazone and
barbiturates

Paracetamol


- inhibits COX only in CNS (COX3 ?) not in periphery ⇒
- effects: analgesic, antipyretic (not antiinflammatory, antirheumatic)



Usage in mixtures with


- codeine, caffeine ⇒ effect enhancement (Korylan tbl.®, Panadol tbl.®, Efferalgan codein tbl. eff.®)
- expectorants (guajfenesin, terpin)
- antitussives (dextromethorphan)
- H₁-antihistamines (pheniramine, chlorphenamine, dimenhydrinate, promethazin, doxylamin) together with α-sympathomimetics (phenylefrine, pseudoephedrine)
- spasmolytics (pitophenon)
- myorelaxants (chlorzoxan, carisoprodol)
- NSAID (acetylsalicylic acid, propyphenazon – Valetol®)

Metabolism of paracetamol




Thiols detoxicating N-acetyl-p-benzoquinoneimine

γ -Glu-Cys-Gly



glutathione





N-acetyl-L-cysteine

mucolytic


ACC®, Mucobene®

Synthesis of paracetamol




Propacetamol – paracetamol prodrug

- for intravenous application




4-(acetylamino)phenyl-N,N-diethylglycinate hydrochloride
2-[4-(acetylamino)phenoxy]-N,N-diethyl-2-oxoethaneaminium chloride
propacetamol hydrochloride

Pro-Dafalgan® (*UPSA Laboratoires*)




Salicylates



salicin
(2-hydroxymethylphenyl)- β -D-glucopyranoside


1827 Leroux: isolation from willow

hydrolysis
oxidation



salicylic acid
2-hydroxybenzoic acid

1838 Piria: the first synthesis
since 1878 used as antipyretic
and antirheumatic



acetylsalicylic acid
2-acetoxybenzoic acid

1897 Felix Hoffmann - industrial
synthesis
1899 – Aspirin® (Bayer)




Felix Hoffmann



Sir John R. Vane



Effects of acetylsalicylic acid



„Wanted“:

- antipyretic
- analgesic
- anti-inflammatory
- antirheumatic
- antithrombotic (\downarrow platelets aggregation) – Anopyrin®




„Unwanted“:

- ulcerogenic
- Rey syndrom in children after viral infection
(hepatopathy, encephalopathy) \Rightarrow kontra-indication in children
- bleeding (e.g. from nose - \downarrow platelets aggregation)

Intoxication = „salicylism“ – infliction of CNS (psychical malfunctions, buzz in ears, dizziness, deafness), metabolic acidosis


Mechanism of action of acetylsalicylic acid (ASA)

- irreversible inhibition of cyclooxygenases by acetylation of serine rest




Metabolism of ASA


- proceeds in liver
- all metabolites are excreted by urine



Syntheses of ASA




Gerhardt, Justus Liebigs Ann. Chem. **87**, 164 (1853)
Gilm, Justus Liebigs Ann. Chem. **112**, 181 (1859)
Kraut, Justus Liebigs Ann. Chem. **150**, 10 (1869)



Felix Hoffmann

Other salicylates




pentakis(acetylosalicyloyloxy)trialuminium dioxide

aloxi

prin

Superpyrin®



2',4'-difluoro-4-hydroxy-1,1'-biphenyl-3-carboxylic acid


diflunisal

Unisal® tbl.

Anthrаниlic acid derivatives – phenamates


= substitution derivatives of 2-phenylaminobenzoic acid

- derived from salicylates by substitution of hydroxy group with (phenyl)amino moiety



- aromatic amino acids
- substituted on the aniline ring only
- inhibit both COX1 and COX2 (selectivity?; COX3?)
- analgesics, antipyretics, antimigraines, anti-inflammatory


Phenamates



R¹	R²	R³	Chemical name	INN / preparation
-CH ₃	-CH ₃	-H	2-(2,3-dimethylphenylamino)-benzoic acid	mephenamic acid
-Cl	-CH ₃	-Cl	2-(2,6-dichloro-3-methylphenylamino)benzoic acid	meclophenamic acid
-CH ₃	-Cl	-H	2-(3-chloro-2-methylphenylamino)benzoic acid	tolphenamic acid Migea rapid®
-H	-CF ₃	-H	2-(3-trifluoromethylphenylamino)benzoic acid	fluphenamic acid

Tolphenamic acid

Synthesis




Kaltenbronn J.S. et al., Arzneim. Forsch **33**, 621-627 (1983)

Selectivity against COXs

$$\frac{IC_{50}(COX1)}{IC_{50}(COX2)} = 10$$

Grossmann C. J. et al., Inflammation Res. **44**, 253-257 (1995)

Niflumic acid and its esters



fluphenamic acid

niflumic acid

- isosteric substitution benzene \Rightarrow pyridine, or $-\text{CH}= \Rightarrow -\text{N=}$
- inhibit both COX1 and COX2
- anti-inflammatory, antirheumatics; usually topically administered

Niflumic acid and its esters



- esters are prodrugs which can better penetrate through the skin

R


2-{[(3-trifluormethyl)phenyl]amino}nicotinic acid

—H **niflumic acid**

Niflугel®, Nifluril®



-||- 2-(morpholine-4-yl)ethylester
morniflumate




-||- 1-oxo-2-(3*H*)-benzofurane-3-ylester
talniflumate

Aryl- and heteroarylalkanoic acids


Structure-activity relationships (SAR)

- the aliphatic part of the molecule is more specific for the effect than the aromatic one



ARY = aryl, heteroaryl


Aryl- and heteroarylacetic acids and their functional derivatives



R = aryl or heteroaryl
Y = OH, NHOH, NHR, OCH₂COOH, or other

- antirheumatics, anti-inflammatory, analgesics, antipyretics
- inhibition of both COX1 and COX2
- adverse effects (AE) like in salicylates

Aryl- and heteroarylacetic acids and their functional derivatives (fenacs)



R = H

[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
indomethacin


- used since 1963

- now mainly topically

Indobene® cps, Bonidon® gel,
Elmetacin® spr

R = OCH₂COOH

[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid
caboxymethylester
aceemetacin



R = H

{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
diclofenac


- used since 1975

Voltaren®, Veral®, Myogit®,
Diclorem®


R = OCH₂COOH

{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid
carboxymethylester
aceclofenac

Heteroarylacetic acids and their derivatives




proglumetacin




[3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazole-4-yl]acetic acid [4-(4-chlorophenyl)-2-phenyl-1,3-thiazole-5-yl]acetic acid
ionazolac **fentiazac**

•isosteres


Aryl- a heteroarylacetic acids



alclofenac




tolmetin




zomepirac

Aryl- a heteroarylacetic acids

- examples of isosterism of rings and functional groups




[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-
1H-indol-3-yl]acetic acid
indomethacin




[6-fluoro-3-(4-methanesulfinylbenzylidene)-2-methyl-
3H-indene-1-yl]acetic acid
sulindac

Nitrogenous functional derivatives of aryl- and heteroarylacetic acids




2-(4-butoxyphenyl)-N-hydroxyacetamide
2-(4-butoxyphenyl)acetohydroxamic acid

bufexamac



1,1'-biphenyl-4-yl-N-pyridine-2-yl-acetamide
difenpiramide




2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]-
N-hydroxyacetamide

2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-yl]-
acetohydroxamic acid

oxametacin

Nabumeton

- a prodrug



4-(6-methoxynaphthalene-2-yl)butan-2-one


nabumetone

Relifex® tbl. obd.

2-(6-methoxynaphthalene-2-yl)acetic acid
(6MNA)

active metabolit

2-aryl- and 2-heteroarylpropionic acids and their functional derivatives




R = aryl or heteroaryl

Y = OH or NHOH

- chiral compounds (S-enantiomer often much more active)
- pain relief, antirheumatics, anti-inflammatory, antipyretics
- inhibition both COX1 and COX2; COX2 a little more
- AE like salicylates but weaker

2-arylpropionic acids




R = OH
(R,S)-2-(4-isobutylphenyl)-
propionic acid

ibuprofen

Brufen®, Ibalgin®

(S)- form = dexibuprofen
Seractil®

R = NHOH **ibuproxam**




2-(3-benzoylphenyl)-
propionic acid

ketoprofen

Fastum®Gel,
Kepabene®tbl

(S)-form =
dexketoprofen
Sympal®
tbl.obd.




(+)-S-2-(6-methoxynaphthalene-2-yl)-
-propionic acid

naproxen

Naprosyn®,
Naprobene®


2-aryl- and 2-heteroarylpropionic acids



2-biphenyl-4-yl-2-fluoropropionic acid


flurbiprofen

Ansaid®, Flugalin®



tiaprofenic acid

Surgam®, Thialgin®



2-[4-(4-chlorophenyl)benzoxazole-5-yl]-propionic acid

benoxaprofen


X = Cl
2-[4-(4-chlorophenyl)benzoxazole-5-yl]-propionic acid

flunoxaprofen

X = F

2-[4-(4-fluorophenyl)benzoxazole-5-yl]-propionic acid

1,2-dihydropyrazole-3-on derivatives





4-substituted-1,5-dimethyl-2-phenyl-1,2-dihydro-3*H*-pyrazole-3-ones

- inhibit both COX1 and COX2
- pain relief, antipyretics
- often used in mixtures

1,2-dihydropyrazole-3-on derivatives

R = H

phenazone, syn. antipyrine [JAN]
obsolete



aminophenazone, syn. aminopyrine
[JAN]

Dinyl® (+ phenacetin, caffeine,
butobarbital, allobarbital)

Eunalgit® inj. (+ allobarbital)



obsolete

propyphenazone

Valetol®, Saridon® (+ paracetamol, caffeine)


Spasmoveralgin neo® (+ papaverin,
phenobarbital, ephedrin, codein,
methylatropin)

•isosterism ↓




metamizol
Novalgin ®


Aminophenazone cancerogeneity



Synthesis of aminophenazone and metamizol




Pyrazolidine-3,5-dione derivatives



- anti-inflammatory, pain relief, antipyretics
- inhibit both COX1 and COX2
- reserved for *m. Bechtereiv* in some countries (CH ...)
- in CZ only external and veterinary preparations
- AE: GIT intolerance, diarrhoea, ulcer disease exacerbation and bleeding into GIT, skin rash, CNS disorders, Na⁺ and water retention, renal malfunctions, bone marrow disturbances

Pyrazolidine-3,5-dione derivatives




R ¹	R ²	Chemical name	INN / preparations
	C ₄ H ₉ -	4-butyl-1,2-diphenylpyrazolidine-3,5-dione	phenylbutazone Butasan® a.u.v
	C ₄ H ₉ -	4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione	oxyphenbutazone Tanderil® sup. <i>reg. in SR</i>
		1,2-diphenyl-4-(4-oxobutyl)pyrazolidine-3,5-dione	kebuzone Ketazon® ung
H-	C ₄ H ₉ -	4-butyl-1-phenylpyrazolidine-3,5-dione	mephebutazone

Heterocyclic enols-“keto-enolic acids“ - oxicams

- contain „keto-enolic“ structural fragment


Tautomerism and dissociation of piroxicam



Oxicams

- acid character
- inhibit both COX1 and COX2 (meloxicam about 3x more COX2)
- effects: anti-inflammatory, pain relief, antipyretic
- using: arthrosis, rheumatoid arthritis ...


Oxicams



4-hydroxy-2-methyl-N-pyridine-2-yl-2*H*-1,2-benzothiazine-3-carboxamide-1,1-dioxide

piroxicam

Arthremin®, Feldene®,
Flamexin® - complex with
β-cyclodextrine



4-hydroxy-2-methyl-N-pyridine-2-yl-2*H*-thieno[2,3-e][1,2]thiazine-3-carboxamide-1,1-dioxide

tenoxicam


R = Cl

6-chloro-4-hydroxy-2-methyl-N-pyridine-2-yl-2*H*-thieno[2,3-e][1,2]thiazine-3-carboxamide-1,1-dioxide

lornoxicam

Xefo®


Oxicams



4-hydroxy-2-methyl-N-
(5-methyl-1,3-thiazole-2-yl)-2*H*-
1,2-benzothiazine-3-carboxamide-1,1-dioxide

meloxicam

Movalis®tbl., Metacam® a.u.v.,
Melokssia®




5-methyl-3-pyridin-2-yl-2*H*,5*H*-
[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3*H*)-dione-
6,6-dioxide

droxicam

Selective COX2 inhibitors

Nimesulide




N-(2-phenoxy-4-nitrophenyl)methanesulfonamide
4'-nitro-2'-phenoxymethanesulfonanilide

nimesulide

Coxtral®, Aulin®, Mesulid®



Nimesulide



- inhibits COX2 4x more than COX1 $\Rightarrow \downarrow \text{AE}$ in GIT and platelets
- antirheumatic, antiarthrotic, pain relief
- AE: hepatotoxicity; increased in fever \Rightarrow not suitable as antipyretic

„Radical analogy“

- substitution benzene \Rightarrow cyclohexane



Young J.M. et. al.,
Inflammation Res. **45**, 246-253 (1996)

N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
NS-398

Selectivity

COX2:COX1

4 : 1


30 : 1

Specific COX2 inhibitors

Coxibs

- aromatic sulfonamides or sulfones (exception: lumiracoxib)
- high selectivity to COX2 \Rightarrow AE to GIT and increased platelets aggregation eliminated
- usage: rheumatoid arthritis, osteoarthritis, primary dysmenorrhea
- also neurodegen. diseases (Alzheimer) – colocalization of cyclines D₁ and E₁ with COX2 in CNS neurones
- AE: \uparrow risk of sudden cardiovascular incidents ($\Leftarrow \downarrow$ production of prostacycline which **inhibits** platelets aggregation but does not affect production of thromboxane which **activates** platelets aggregation), skin damage (mainly valdecoxib)

Coxibs




4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide

celecoxib

Celebrex®

Onsenal® – as an orphan drug for
familial adenomatous polyposis (FAP)
only

Selectivity
COX2 : COX1 30 : 1




5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine

etoricoxib

Arcoxia®

340 : 1

Coxibs



N-{[4-(5-methyl-3-phenylisoxazole-4-yl)phenyl]sulfonyl}propanamide


parecoxib

- allergic skin reactions mainly in persons hypersensitive to sulfonamides

Dynastat® - for postoperative pain only

Selectivity

COX2 : COX1



4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one


rofecoxib

~~Ceeoxx®, Vioxx®~~

withdrawn due to dangerous cardiovascular effects

270 : 1


Coxibs



4-(5-methyl-3-phenylisoxazole-4-yl)benzenesulfonamide

valdecoxib

~~Bextra® withdrawn~~




4-(4-cyclohexyl-2-methyl-1,3-oxazole-5-yl)-2-fluorobenzenesulfonamide

tilmacoxib

Selectivity

COX2 : COX1 60 : 1

Coxibs




2-(2-fluoro-6-chlorophenylamino)-5-methylphenylacetic acid

lumiracoxib

Prexige®

For comparison:



diclophenac